TGFB1 and depressive symptom measurement: Deregulation of TGF-β1 has been proposed for multiple neurological disorders including AIDS dementia complex, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), MS, anxiety, depression, and schizophrenia (Kashima and Hata, 2018).